Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225913 · ClinicalTrials.gov registry record · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
A Phase 4 study of Asthma, sponsored by Gelb, Arthur F., M.D..
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01225913 is a Phase 4 study of Asthma that is actively recruiting participants, run by Gelb, Arthur F., M.D.. The registered enrollment target is 50 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01225913, a Phase 4 study of Asthma, is actively recruiting participants, sponsored by Gelb, Arthur F., M.D..
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.
Conditions Studied
Interventions
- DRUG fluticasone/salmeterol in all asthmatics
- DRUG budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Study Locations (1)
California
- Arthur F Gelb Medical Corporation - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-10 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225913
The ClinicalTrials.gov registry entry for NCT01225913 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Gelb, Arthur F., M.D., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which fluticasone/salmeterol in all asthmatics is the first listed.
NCT01225913 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01225913 about?
NCT01225913 is a clinical study titled "Mechanism(s) of Airflow Limitation During Exacerbation of Asthma". The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2ag...
What is the current status of trial NCT01225913?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2007-10. Estimated completion is 2027-06.
What conditions does trial NCT01225913 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01225913?
The interventions under investigation include: fluticasone/salmeterol in all asthmatics (DRUG), budesonide/formoterol or fluticasone/salmeterol in all asthmatics (DRUG).
Who is sponsoring clinical trial NCT01225913?
This trial is sponsored by Gelb, Arthur F., M.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01225913 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.